Article result template
I'm a little template short and blank. I link to void and keep hidden out.
2024-10-31T17:36:14+0000
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
I'm a little template short and blank. I link to void and keep hidden out.
2024-10-31T17:36:14+0000
Trial results from Eli Lilly add to a growing body of evidence that suggests GLP-1 drugs, which include treatments like Lilly’s Mounjaro and Novo Nordisk’s Wegovy, have medical benefits beyond diabetes and weight loss.
2024-04-17T16:11:00+0100
Novo Nordisk has surpassed Tesla in terms of market cap after positive early trial data for its hotly awaited new obesity drug. IGTV's Angeline Ong takes a closer look at a weight-loss drug sector set to be worth $100 bln by 2030.
2024-03-08T14:55:35+0000
Merck & Co shares rise after solid sales of its cancer immunotherapy drug Keytruda helped it report better-than-expected Q4 results. IGTV's Angeline Ong takes a look at the reaction and what’s in the pipeline for the drugmaker.
2024-02-01T16:29:53+0000
Global syringe-filling facilities are struggling to cope with rising demand for anti-obesity drugs, which require injection pens. IGTV's @AngelineOng investigates which companies could benefit from ‘fill-finish’ demand.
2023-11-24T13:25:33+0000
The drug giant has purchased a potential blockbuster obesity drug from Chinese firm Eccogene
2023-11-11T11:11:04+0000